Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing agreement with the Trump ...
The Cambridge, Massachusetts-based company – known as FogPharma until a rebrand in 2024 – needs cash for pivotal trials of ...
In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...
Hetlioz (tasimelteon) has been approved in the US for a few years to treat sleep disorders affecting people who are blind or ...
In the same week that Servier announced its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has ...
For over 60 years, the search for an effective pharmacologic treatment for refractory or unexplained chronic cough has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback